Multiple Sclerosis Therapeutic Market - Top Companies and Manufacturers

Companies Dominating the Multiple Sclerosis Therapeutic Landscape

Companies in the multiple sclerosis therapeutics adopting several strategies to strengthen their position and enhance their product portfolios. Extensive investment in R&D activities, and launching innovative new treatments, particularly in biologics and oral therapies are two of the highly adopted strategies. Companies are also focusing on securing regulatory approvals for new drugs. Collaboration and acquisition activities are maintaining the competition in the global multiple sclerosis therapeutic market. For instance, in October 2020, Eli Lilly and Company announced the acquisition of Disarm Therapeutics for an upfront payment of $135.0 million. Some of the prominent players include:

• Abbvie Inc.
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• Amgen Inc.
• Acorda Therapeutics, Inc.
• Biogen Inc.
• Bayer AG
• Bristol-Myers Squibb Company.
• F. Hoffman-La Roche Ltd
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Sanofi
• Viatris Inc.